<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TPX</journal-id>
<journal-id journal-id-type="hwp">sptpx</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Pathol</journal-id>
<journal-title>Toxicologic Pathology</journal-title>
<issn pub-type="ppub">0192-6233</issn>
<issn pub-type="epub">1533-1601</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0192623312450629</article-id>
<article-id pub-id-type="publisher-id">10.1177_0192623312450629</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Renal Pathophysiologic Role of Cortical Tubular Inclusion Bodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Radi</surname>
<given-names>Zaher A.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312450629">1</xref>
<xref ref-type="corresp" rid="corresp1-0192623312450629"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stewart</surname>
<given-names>Zachary S.</given-names>
</name>
<xref ref-type="aff" rid="aff1-0192623312450629">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grzemski</surname>
<given-names>Felicity A.</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623312450629">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bobrowski</surname>
<given-names>Walter F.</given-names>
</name>
<xref ref-type="aff" rid="aff2-0192623312450629">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0192623312450629"><label>1</label>Pfizer Worldwide Research and Development, Drug Safety R&amp;D, Cambridge, Massachusetts, USA</aff>
<aff id="aff2-0192623312450629"><label>2</label>Pfizer Worldwide R&amp;D, Drug Safety R&amp;D, Groton, Connecticut, USA</aff>
<author-notes>
<corresp id="corresp1-0192623312450629">Zaher A. Radi, Pfizer Worldwide Research Development, 35 Cambridge Park Dr., MA 02140, USA; e-mail: <email>zaher.radi@pfizer.com</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>1</issue>
<fpage>32</fpage>
<lpage>37</lpage>
<permissions>
<copyright-statement>© 2013 by The Author(s)</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Society of Toxicologic Pathology</copyright-holder>
</permissions>
<abstract>
<p>Renal tubular inclusion bodies are rarely associated with drug administration. The authors describe the finding of renal cortical tubular intranuclear and intracytoplasmic inclusion bodies associated with the oral administration of a norepinephrine/serotonin reuptake inhibitor (NSRI) test article in Sprague-Dawley (SD) rats. Rats were given an NSRI daily for 4 weeks, and kidney histopathologic, ultrastructural pathology, and immunohistochemical examinations were performed. Round eosinophilic intranuclear inclusion bodies were observed histologically in the tubular epithelial cells of the renal cortex in male and female SD rats given the NSRI compound. No evidence of degeneration or necrosis was noted in the inclusion-containing renal cells. By ultrastructural pathology, inclusion bodies consisted of finely granular, amorphous, and uniformly stained nonmembrane-bound material. By immunohistochemistry, inclusion bodies stained positive for <sc>d</sc>-amino acid oxidase (DAO) protein. In addition, similar inclusion bodies were noted in the cytoplasmic tubular epithelial compartment by ultrastructural and immunohistochemical examination.  This is the first description of these renal inclusion bodies after an NSRI test article administration in SD rats. Such drug-induced renal inclusion bodies are rat-specific, do not represent an expression of nephrotoxicity, represent altered metabolism of <sc>d</sc>-amino acids, and are not relevant to human safety risk assessment.</p>
</abstract>
<kwd-group>
<kwd>inclusion bodies</kwd>
<kwd>renal</kwd>
<kwd>
<sc>d</sc>-amino acid oxidase.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0192623312450629">
<title>Introduction</title>
<p>The test article in this toxicology study is a norepinephreine (NE)/serotonin (5-HT) reuptake inhibitor (NSRI) that was developed and investigated for the treatment of fibromyalgia (FM). NSRI increases both NE and 5-HT levels via binding to presynaptic reuptake transporters in the central nervous system (CNS). FM is a chronic pain disorder that is characterized by widespread musculoskeletal pain without demonstrable structural abnormalities or evidence-based pathophysiological mechanisms (<xref ref-type="bibr" rid="bibr17-0192623312450629">Lawson 2002</xref>). Characteristic clinical features of FM include headaches, migraines, fatigue, depression, and morning stiffness (<xref ref-type="bibr" rid="bibr17-0192623312450629">Lawson 2002</xref>). The exact etiology of FM is currently unknown. Among the several hypotheses proposed regarding FM pathogenesis, abnormal physiological processing of nociceptive neurons resulting in increased pain perception has also been proposed (<xref ref-type="bibr" rid="bibr21-0192623312450629">Nijs and Van Houdenhove 2009</xref>). In fact, alterations in central pain processing have been demonstrated in FM patients, and therefore have been suggested to play a role in the etiopathogenesis of FM (<xref ref-type="bibr" rid="bibr8-0192623312450629">Gracely et al. 2002</xref>; <xref ref-type="bibr" rid="bibr25-0192623312450629">Staud et al. 2001</xref>). </p>
<p>The primary neuronal transmitters involved in pain perception and processing are 5-HT and NE. Therefore, 5-HT and NE have been implicated in the mediation of analgesic mechanisms via the descending inhibitory pain pathways in the CNS. It is proposed that dysfunction of 5-HT and NE pathways is a potential mechanism for the chronic pain in FM patients. The theory is that tricyclic antidepressant’s pharmacologic efficacy in FM is related to inhibiting reuptake of 5-HT and NE into the neuronal terminal and thereby reducing pain perception and processing in patients with FM (<xref ref-type="bibr" rid="bibr17-0192623312450629">Lawson 2002</xref>).  Indeed, pharmacologic studies with antidepressants showed that inhibition of both the 5-HT and NE reuptake transporters were more effective in treating FM than inhibition of either transporter alone (<xref ref-type="bibr" rid="bibr7-0192623312450629">Goldenberg et al. 1996</xref>). Additionally, some clinical studies showed that using dual 5-HT and NE reuptake inhibitors, duloxetine and milnacipran, demonstrated efficacy in patients with FM, providing pain relief and psychotherapeutic benefits (<xref ref-type="bibr" rid="bibr2-0192623312450629">Arnold et al. 2004</xref>; <xref ref-type="bibr" rid="bibr16-0192623312450629">Kyle, Dugan, and Testerman 2010</xref>). Thus, NSRI inhibitor was developed by Pfizer Worldwide Research and Development to treat FM.</p>
<p>The physiologic function of <sc>d</sc>-amino acid oxidases (DAO) is to metabolize <sc>d</sc>-amino acids. In mammals, DAO are approximately 39 kDa proteins, consist of 347 amino acid residues, and are mainly present in the kidneys, liver, and brain. The most abundant <sc>d</sc>-amino acids in mammals are <sc>d</sc>-serine and <sc>d</sc>-aspartate (<xref ref-type="bibr" rid="bibr22-0192623312450629">Ohide et al. 2011</xref>). Large amounts of <sc>d</sc>-serine are present in the brain of mammalian species and function as a modulator of neurotransmission.  <sc>d</sc>-serine binds to the <sc>n</sc>-Methyl-<sc>d</sc>-Aspartate (NMDA) subtype of glutamate receptors and functions as a co-agonist (<xref ref-type="bibr" rid="bibr22-0192623312450629">Ohide et al. 2011</xref>). DAO has been associated with neurologic pathologic conditions such as schizophrenia and amyotrophic lateral sclerosis (<xref ref-type="bibr" rid="bibr3-0192623312450629">Chumakov et al. 2002</xref>; <xref ref-type="bibr" rid="bibr19-0192623312450629">Mitchell et al. 2010</xref>). However, the renal pathophysiologic role of DAO is poorly understood. The pathophysiologic mechanism of DAO nuclear and cytosolic accumulation is likely related to peroxisome proliferation and enzyme induction mediated through peroxisome proliferator activated receptor α (PPARα). Peroxisome proliferation is mediated through PPARα, which mediates the effects of induced peroxisome proliferators on liver and kidney, including the induction of peroxisomal, mitochondrial, and microsomal enzymes (<xref ref-type="bibr" rid="bibr23-0192623312450629">Peters et al. 1996</xref>). Increased DAO activity has been demonstrated in kidneys of rats exposed to ciprofibrate, a PPARα agonist (<xref ref-type="bibr" rid="bibr26-0192623312450629">Stefanini et al. 1999</xref>). In addition, PPARα is found predominately in the renal cortex proximal convoluted tubules (<xref ref-type="bibr" rid="bibr28-0192623312450629">Yang et al. 1999</xref>). Therefore, DAO expression in the kidneys of rats appears to be under the control of PPARα.</p>
<p>To assess the preclinical safety profile of the NSRI test article, a 4-week toxicology study was conducted in Sprague-Dawley (SD) male and female rats. An unexpected finding at the end of the study was the presence of inclusion bodies in the renal tubular epithelial cells without tissue damage or inflammation as assessed by light microscopic examination. Inclusion bodies in the renal tubular epithelium are typically seen in some viral infections or lead poisoning, but rarely associated with drug administration. Similar inclusions have been reported in the literature in male and female Fisher 344 rats given propiverine (<xref ref-type="bibr" rid="bibr6-0192623312450629">Dietrich et al. 2008</xref>). Propiverine is an anti-cholinergic drug used to treat neurogenic detrusor overactivity and overactive bladder (<xref ref-type="bibr" rid="bibr1-0192623312450629">Alloussi et al. 2010</xref>). To the best of our knowledge, this article is the first description of intranuclear and intracytoplasmic inclusion bodies in renal tubular epithelial cells associated with NSRI test article administration in SD rats. The relevance of such kidney inclusion bodies to human safety risk assessment is discussed.</p>
</sec>
<sec id="section2-0192623312450629" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-0192623312450629">
<title>Animals</title>
<p>Male and female Sprague-Dawley [(Crl:CD(SD)] rats obtained from Charles River Laboratories were used for this 4-week toxicology study. Animals were 7 to 8 weeks old and weighed 150 to 275 g at the start of dosing. Clinically acceptable animals were assigned to dose groups using a computer-assisted randomization procedure. Animals were individually housed in stainless steel cages. Standard procedures and conditions were applied for animal care, feeding, and maintenance of room, caging, and environment. Animals were fed Certified Rodent Diet ad libitum, and water was supplied ad libitum via an automatic watering system. Animals were fasted overnight prior to blood collection for clinical laboratory measurements at scheduled necropsy. This study was conducted in accordance with current guidelines for animal welfare (National Research Council, 1996). The procedures used in this study were reviewed and approved by the Institutional Animal Care and Use Committee.</p>
</sec>
<sec id="section4-0192623312450629">
<title>Experimental Design</title>
<p>Toxicity study animals (10 rats/sex/group) and toxicokinetics (TK) study animals (4/sex/group) received the test article, a dual inhibitor of NE and 5-HT reuptake, NSRI, which was synthesized by Pfizer Worldwide Research and Development. Dosing suspensions were prepared approximately weekly in aqueous 1% methylcellulose at doses of 3, 10, or 30 mg/kg/day. Animals were dosed once daily by oral gavage for 4 weeks. Control animals received the vehicle alone. </p>
</sec>
<sec id="section5-0192623312450629">
<title>Experimental Procedures</title>
<sec id="section6-0192623312450629">
<title>Clinical signs, ophthalmic examination, body weight and food consumption</title>
<p>Animals were observed twice daily for clinical signs. Ophthalmic examination was conducted once during the predosing and once during the last 7 days of dosing. Body weights were determined once prior to dosing and weekly thereafter. Food consumption was determined weekly and at scheduled termination. </p>
</sec>
<sec id="section7-0192623312450629">
<title>Clinical pathology</title>
<p>Hematological and clinical chemistry parameters were evaluated on day 28 at scheduled termination in animals designated for main study toxicologic assessment. Blood samples were analyzed for hematology parameters (absolute and differential blood counts). Serum was analyzed for clinical chemistry parameters: glucose, total cholesterol, total bilirubin, total protein, albumin, globulin, albumin/globulin ratio, phosphorus, calcium, chloride, sodium, potassium, creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and urea nitrogen.</p>
</sec>
<sec id="section8-0192623312450629">
<title>Toxicokinetics (TK)</title>
<p>Toxicokinetic parameters were assessed on days 1 and 29 from animals designated for TK assessment. Following blood sampling, animals designated for TK assessment were euthanized and discarded. No other procedures were conducted on these animals. Serum samples were analyzed for NSRI drug concentration using a validated Liquid chromatographic-tandem mass spectrometric (LC/MS/MS) method. The TK parameters of maximum concentration (Cmax), time to Cmax (Tmax), and area under the concentration–time curve (AUC) were determined. </p>
</sec>
</sec>
<sec id="section9-0192623312450629">
<title>Anatomic Pathology</title>
<sec id="section10-0192623312450629">
<title>Organ weights and ratios, gross pathology, histopathology</title>
<p>Necropsies were performed on all animals designated for main study toxicologic assessment. The brain, kidneys, and liver were weighed at scheduled necropsy. Organ-to-body weight and organ-to-brain weight ratios were calculated. Representative samples of the kidneys and liver were collected at necropsy, fixed in 10% buffered formalin, and processed for light microscopic examination. Kidney and liver tissues from all animals were sectioned, stained with hematoxylin and eosin (H&amp;E), and evaluated microscopically. </p>
</sec>
</sec>
<sec id="section11-0192623312450629">
<title>Immunohistochemistry for DAO</title>
<p>To analyze the protein expression of DAO, 4 µm sections were cut from formalin-fixed, paraffin-embedded blocks, mounted on positively charged glass slides, dried, and then loaded on the automated immunostainer (room temperature using a Ventana Discovery [Ventana Medical Systems, Tucson, AZ]).  Slides were deparaffinized and then rehydrated. Enzymatic antigen retrieval was completed with a Ventana specialty solution Protease 2 (Ventana Medical Systems).  Endogenous Biotin was blocked using the A/B Kit (Ventana medical Systems) Sections were incubated 4 min each in Avidin and Biotin steps.</p>
<p>Automation included exposure to 100 µL of primary anti-DAO antibody (Rockland Inc.) diluted at 1:1,000 (90 µg/ml) with reagent diluent (Ventana Medical Systems) at room temperature for 120 min.  100 µl of the Secondary Antibody a biotinylated anti-sheep (Vector Labs) diluted at 1:200 with reagent diluent (Ventana Medical Systems) was applied to each section for 30 min at room temperature.  Sections were again rinsed and chromagenically labeled using the DABmap Detection Kit substrate solutions (Ventana Medical Systems), followed by counterstaining with Hematoxylin and then Bluing Reagent for 4 min each, removed from the autostainer, washed in warm water, dehydrated through graded alcohol, cleared in xylene, and cover slipped.  Control reactions included (1) sections incubated with the omission of primary antibody and processed as mentioned above and (2) sections incubated with normal sheep Immunoglobulin G (IgG) (90 µg/ml) instead of the primary antibody and processed as above.  In addition, periodic acid Schiff (PAS) and acid-fast histochemical staining were performed on kidney sections.</p>
</sec>
<sec id="section12-0192623312450629">
<title>Ultrastructural Pathology</title>
<p>Minced tissue samples were fixed in 2.5% glutaraldehyde + 2% formaldehyde in 0.1M sodium phosphate buffer, post-fixed in 0.1M sodium phosphate buffered 1% osmium tetroxide, dehydrated through a graded ethanol series, and embedded in epoxy resin. Sections (approximately 0.6 µm thick) were prepared from two randomly selected epoxy resin tissue-bearing blocks of each selected animal, stained with Toluidine Blue O, and examined using light microscopy. Blocks were trimmed based on light microscopic findings, and sections (approximately 70 nm thick) were prepared from each of the two selected blocks of each animal, stained with uranyl acetate and lead citrate examined in a Hitachi H-7000 transmission electron microscope. Digital images were acquired (AMT, Inc.) and image files were transferred to a secure image server, and appended to the present report. All processes were performed under Good Laboratory Practices guidelines and according to standard operational procedures.</p>
</sec>
</sec>
<sec id="section13-0192623312450629">
<title>Results</title>
<sec id="section14-0192623312450629">
<title>Clinical Signs, Ophthalmic Examination, Body Weight, and Food Consumption</title>
<p>There was no significant effect on body weight at doses ≤ 10 mg/kg/day. Body weight was decreased up to 11% in both sexes at 30 mg/kg/day during the study period. Food consumption was decreased initially but recovered over time. All other parameters (clinical signs and ophthalmic examination) were within normal limits.</p>
</sec>
<sec id="section15-0192623312450629">
<title>Clinical Pathology</title>
<p>No significant NSRI-related changes were observed in hematology parameters.  Mean serum total cholesterol was increased 27% in 30 mg/kg/day males and 29% and 62% in 10 and 30 mg/kg/day females, respectively. All other clinical chemistry parameters were within normal limits. </p>
</sec>
<sec id="section16-0192623312450629">
<title>Toxicokinetics</title>
<p>In general, systemic exposure increased with increasing dose (<xref ref-type="table" rid="table1-0192623312450629">Table 1</xref>). Exposure to the NSRI compound at all doses was higher on day 29 compared to day 1. The overall mean AUC (0–24) values ranged from 1.6- to 3.7-fold higher, while overall mean Cmax values ranged from 1.2- to 2.7-fold higher on day 29 compared to day 1. No test article levels were determined in plasma samples obtained from controls.</p>
<table-wrap id="table1-0192623312450629" position="float">
<label>Table 1.</label>
<caption>
<p>Toxicokinetic exposure after norepinephreine (NE)/serotonin (5-HT) reuptake inhibitor (NSRI) oral dosing in male and female Sprague-Dawley rats.</p>
</caption>
<graphic alternate-form-of="table1-0192623312450629" xlink:href="10.1177_0192623312450629-table1.tif"/>
<table>
<thead>
<tr>
<th>Dose (mg/kg)</th>
<th>Day</th>
<th>Cmax (µg/mL)</th>
<th>Tmax (hr)</th>
<th>AUC(0–24)(µg.hr/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>1</td>
<td>0.0903</td>
<td>1</td>
<td>0.63</td>
</tr>
<tr>
<td>
</td>
<td>29</td>
<td>0.317</td>
<td>1.38</td>
<td>2.93</td>
</tr>
<tr>
<td>10</td>
<td>1</td>
<td>0.579</td>
<td>1.75</td>
<td>6.67</td>
</tr>
<tr>
<td>
</td>
<td>29</td>
<td>1.26</td>
<td>1.88</td>
<td>17.2</td>
</tr>
<tr>
<td>30</td>
<td>1</td>
<td>1.4</td>
<td>4.75</td>
<td>24.7</td>
</tr>
<tr>
<td>
</td>
<td>29</td>
<td>5.19</td>
<td>3</td>
<td>85</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section17-0192623312450629">
<title>Anatomic Pathology</title>
<sec id="section18-0192623312450629">
<title>Kidney and liver weights and ratios and gross pathology</title>
<p>When compared to controls, no changes in absolute kidney or liver weights or relative ratios (relative to body or brain) or gross pathology observations were noted in the kidneys or liver at necropsy.</p>
</sec>
<sec id="section19-0192623312450629">
<title>Histopathology, ultrastructural pathology, and immuno-histochemistry</title>
<p>NSRI-related light microscopic changes were evident in kidney sections from rats at ≥10 mg/kg/day. Light microscopic changes in the kidney were characterized by the presence of intranuclear and cytoplasmic inclusion bodies in tubular epithelial cells of the renal cortex but not in the medulla. Inclusions were eosinophilic, round, and surrounded by a clear halo consistent with chromatin margination (<xref ref-type="fig" rid="fig1-0192623312450629">Figure 1</xref>). Inclusions were PAS and acid-fast negative. This acidic nature of such inclusions was most consistent with protein content. Renal tubular epithelial cells containing these inclusions did not exhibit any features suggestive of cellular degeneration, necrosis, or inflammation, and kidneys were otherwise within normal limits.</p>
<fig id="fig1-0192623312450629" position="float">
<label>Figure 1.</label>
<caption>
<p>Kidney histopathology section from a Sprague-Dawley rat treated with a norepinephreine (NE)/serotonin (5-HT) reuptake inhibitor (NSRI). Note cytoplasimc and intranuclear inclusion bodies (arrows). H&amp;E. 40×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312450629-fig1.tif"/>
</fig>
<p>By immunohistochemical examination, inclusions were strongly positive for <sc>dao</sc> protein. Large and strongly positive inclusions were also evident in the cytoplasm of renal tubular epithelial cells (<xref ref-type="fig" rid="fig2-0192623312450629">Figure 2</xref>).</p>
<fig id="fig2-0192623312450629" position="float">
<label>Figure 2.</label>
<caption>
<p>Kidney section immunohistochemical staining from a Sprague-Dawley rat treated with a norepinephreine (NE)/serotonin (5-HT) reuptake inhibitor (NSRI). Note strongly DAO-positive intranuclear and intracytoplasmic inclusion bodies evident in the renal tubular epithelial cells. 40×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312450629-fig2.tif"/>
</fig>
<p>By ultrastructural pathologic examination, intranuclear renal cortical tubular epithelium inclusions consisted of nonmembrane-bound finely granular, amorphous, and uniformly stained material of moderate electron density that displaced the nucleoli and surrounding chromatin to the periphery (<xref ref-type="fig" rid="fig3-0192623312450629">Figure 3A</xref> and B). Inclusions of similar morphology were also identified in the cytoplasm. There was no evidence of damage or alterations to any of the cellular organelles.</p>
<fig id="fig3-0192623312450629" position="float">
<label>Figure 3.</label>
<caption>
<p>Electron photomicrograph of kidney from a Sprague-Dawley rat treated with a norepinephreine (NE)/serotonin (5-HT) reuptake inhibitor (NSRI). (A) Note intranuclear and intracytoplasmic renal Inclusions. 2,100×. (B) inclusions consisted of nonmembrane-bound finely granular, amorphous, and uniformly stained material of moderate electron density that displaced the nucleoli and surrounding chromatin to the periphery. 11,000×.</p>
</caption>
<graphic xlink:href="10.1177_0192623312450629-fig3.tif"/>
</fig>
</sec>
</sec>
</sec>
<sec id="section20-0192623312450629">
<title>Discussion</title>
<p>A test article with dual NSRI inhibition in SD rats was associated with intranuclear and cytoplasmic inclusion bodies in renal tubules in the kidney as assessed by histopathology, histochemistry, immunohistochemistry, and ultrastructural pathology. These inclusions were identified by immunohistochemistry as DAO-positive. The presence of these inclusions in tubular epithelial cells was not associated with pathologic changes or adverse renal function effects as assessed by kidney weights, clinical chemistry parameters, and renal tubular epithelium morphology. The inclusions were not associated with any morphological evidence of renal tubular cellular injury at the light or electron microscopic level. There is no literature, to the best of our knowledge, on the presence of such drug-induced inclusions with an NSRI drug or in the SD rat strain used in safety assessment studies. Published literature indicates that DAO-positive intranuclear and cytoplasmic inclusions were observed in the renal tubular epithelial cells of the F344 rat strain dosed with another drug, propiverine, for up to 52 weeks (<xref ref-type="bibr" rid="bibr20-0192623312450629">Nakano et al. 1989</xref>; <xref ref-type="bibr" rid="bibr27-0192623312450629">Yamashita et al. 1990</xref>; <xref ref-type="bibr" rid="bibr5-0192623312450629">Day, Heussner, and O’Brien 2006</xref>; <xref ref-type="bibr" rid="bibr9-0192623312450629">Gramatte et al. 2006</xref>; <xref ref-type="bibr" rid="bibr10-0192623312450629">Heussner et al. 2006</xref>; <xref ref-type="bibr" rid="bibr24-0192623312450629">Runkel et al. 2006</xref>). Similar to our study with the NSRI test article in SD rats, the presence of these inclusions was not associated with morphological or pathological evidence of renal damage in F344 rats (<xref ref-type="bibr" rid="bibr27-0192623312450629">Yamashita et al. 1990</xref>; <xref ref-type="bibr" rid="bibr5-0192623312450629">Day, Heussner, and O’Brien 2006</xref>; <xref ref-type="bibr" rid="bibr9-0192623312450629">Gramatte et al. 2006</xref>; <xref ref-type="bibr" rid="bibr24-0192623312450629">Runkel et al. 2006</xref>). </p>
<p>Immunohistochemical staining identified these inclusions as DAO-positive. DAO is an enzyme that catalyzes oxidative deamination of <sc>d</sc>-amino acids (<xref ref-type="bibr" rid="bibr11-0192623312450629">Koibuchi et al. 1995</xref>). <sc>d</sc>-amino acids administered to animals are absorbed by the intestine and transported through the blood stream to solid tissues where they are oxidized <italic>in vivo</italic> by DAO and <sc>d</sc>-aspartate oxidase to produce ammonia and hydrogen peroxide and the keto acid corresponding to the amino acid ingested (<xref ref-type="bibr" rid="bibr4-0192623312450629">D'Aniello et al. 1993</xref>). DAO is expressed in the kidneys, liver, and brain. In the kidneys, DAO is expressed in several species such as rats, mice, dogs, pigs, and humans (<xref ref-type="bibr" rid="bibr29-0192623312450629">Zaar et al. 1986</xref>; <xref ref-type="bibr" rid="bibr11-0192623312450629">Koibuchi et al. 1995</xref>; <xref ref-type="bibr" rid="bibr4-0192623312450629">D'Aniello et al. 1993</xref>). DAO is located in the peroxisomes of the renal epithelial cells of the proximal tubules. DAO expression is much higher in rat renal peroxisomes than in liver peroxisomes (<xref ref-type="bibr" rid="bibr29-0192623312450629">Zaar et al. 1986</xref>). In rats, a specific enzyme induction for these <sc>dao</sc>s exists in young rats following ingestion of free <sc>d</sc>-amino acids by females (the mother). When the female rat ingests <sc>d</sc>-Ala or <sc>d</sc>-Asp during pregnancy and suckling, an increase in DAO or <sc>d</sc>-aspartate oxidase was observed in the liver and kidneys of its offspring. Therefore, the <italic>in vivo </italic>biological role of DAO in animals is thought to act as detoxifying agents to metabolize <sc>d</sc>-amino acids, which may have accumulated during aging (<xref ref-type="bibr" rid="bibr4-0192623312450629">D'Aniello et al. 1993</xref>). Mouse DAO has a high homology (94%) to that of the rat (<xref ref-type="bibr" rid="bibr6-0192623312450629">Dietrich et al. 2008</xref>). Human DAO, on the other hand, has 81% similarity to rat DAO (<xref ref-type="bibr" rid="bibr12-0192623312450629">Konno 1998</xref>, <xref ref-type="bibr" rid="bibr13-0192623312450629">2001</xref>). Thus, rat DAO appears to be distinct from that of humans.</p>
<p>There is a DAO-deficient LEA/SENDAI rat model (<xref ref-type="bibr" rid="bibr18-0192623312450629">Maekawa et al. 2005</xref>; <xref ref-type="bibr" rid="bibr15-0192623312450629">Konno et al. 2009</xref>). Although there is significant deficiency in DAO levels, this model lacks renal pathological changes. In propiverine studies in F344 rats, DAO-positive inclusions were restricted to in the nuclei and the cytosol of the renal cortical proximal tubules of both sexes (<xref ref-type="bibr" rid="bibr6-0192623312450629">Dietrich et al. 2008</xref>). No pathological lesions in the liver or kidney, beyond the excessive renal accumulation of cytosolic and nuclear DAO-positive inclusions, were observed in either male or female F344 rats following propiverine treatment. This is consistent with our data. An inbred mutant strain (ddY/DAO) lacking DAO activity was established (<xref ref-type="bibr" rid="bibr14-0192623312450629">Konno et al. 2010</xref>). These mice lack any evidence of pathologic abnormalities in the kidney (Knno et al. 2010).</p>
<p>Hepatic clearance is the major route of elimination for our NSRI compound. Propiverine metabolism is similar to our NSRI compound. Propiverine is rapidly absorbed and undergoes extensive and first pass metabolism in the liver to the main metabolite, propiverine N-oxide (<xref ref-type="bibr" rid="bibr6-0192623312450629">Dietrich et al. 2008</xref>). It is interesting to note that the renal inclusions seen with propiverine in rats were not seen in B6C3F1 mice (<xref ref-type="bibr" rid="bibr6-0192623312450629">Dietrich et al. 2008</xref>). Additionally, no inclusions were seen with propiverine in dogs. Consistent with these data, in another study with NSRI in dogs no inclusions were observed. DAO-positive inclusions in the kidneys of rats only but not dogs or mice, despite high homology to mice, strongly suggest that these are rat-specific drug-induced renal inclusions. We did not have a recovery arm in our study. However, partial recovery of propiverine-induced inclusions after a 5-week recovery period suggests that these test article–induced inclusions would be reversible (<xref ref-type="bibr" rid="bibr20-0192623312450629">Nakano et al. 1989</xref>). Therefore, these renal findings appear to be species-specific, reversible, and not relevant to human safety risk assessment. To the best of our knowledge, this article is the first description of intranuclear and intracytoplasmic inclusion bodies in renal tubular epithelial cells associated with NSRI test article administration in SD rats.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0192623312450629">
<p>The authors declared the following potential conflict of interest: The authors are employed by Pfizer Inc.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0192623312450629">
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by Pfizer Inc.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="term1-0192623312450629">AUC</term>
<def>
<p>area under the concentration–time curve</p>
</def>
</def-item>
<def-item>
<term id="term2-0192623312450629">CNS</term>
<def>
<p>central nervous system</p>
</def>
</def-item>
<def-item>
<term id="term3-0192623312450629">DAO</term>
<def>
<p>
<sc>d</sc>-amino acid oxidase</p>
</def>
</def-item>
<def-item>
<term id="term4-0192623312450629">FM</term>
<def>
<p>fibromyalgia</p>
</def>
</def-item>
<def-item>
<term id="term5-0192623312450629">H&amp;E</term>
<def>
<p>hematoxylin and eosin</p>
</def>
</def-item>
<def-item>
<term id="term6-0192623312450629">NMDA</term>
<def>
<p>
<sc>n</sc>-Methyl-<sc>d</sc>-Aspartate</p>
</def>
</def-item>
<def-item>
<term id="term7-0192623312450629">NSRI</term>
<def>
<p>norepinephrine/serotonin reuptake inhibitor</p>
</def>
</def-item>
<def-item>
<term id="term8-0192623312450629">PAS</term>
<def>
<p>periodic acid Schiff</p>
</def>
</def-item>
<def-item>
<term id="term9-0192623312450629">PPARα</term>
<def>
<p>peroxisome proliferator activated receptor α</p>
</def>
</def-item>
<def-item>
<term id="term10-0192623312450629">SD</term>
<def>
<p>Sprague-Dawley</p>
</def>
</def-item>
<def-item>
<term id="term11-0192623312450629">TK</term>
<def>
<p>toxicokinetics</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alloussi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mürtz</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Gerhardt</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Heinrich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hellmis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Horn</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Marschall-Kehrel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Niklas</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Raabe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rössler</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Seibt</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Siemer</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schultz-Lampel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wiedeking</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Alloussi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bock</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Strugala</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Madersbacher</surname>
<given-names>H</given-names>
</name>
</person-group>. (<year>2010</year>). <article-title>Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study</article-title>. <source>BJU Int</source> <volume>106</volume>, <fpage>550</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr2-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arnold</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Crofford</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Wohlreich</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Detke</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Iyengar</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goldstein</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder</article-title>. <source>Arthritis Rheum</source> <volume>50</volume>, <fpage>2974</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr3-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chumakov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Blumenfeld</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guerassimenko</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Cavarec</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Palicio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Abderrahim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bougueleret</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>La Rosa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Puech</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tahri</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cohen-Akenine</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Delabrosse</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lissarrague</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Picard</surname>
<given-names>F. P.</given-names>
</name>
<name>
<surname>Maurice</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Essioux</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Millasseau</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Grel</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Debailleul</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Simon</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Caterina</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dufaure</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Malekzadeh</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Belova</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Luan</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Bouillot</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sambucy</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Primas</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Saumier</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Boubkiri</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martin-Saumier</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nasroune</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Peixoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Delaye</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pinchot</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Bastucci</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guillou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chevillon</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sainz-Fuertes</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Meguenni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aurich-Costa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cherif</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gimalac</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Van Duijn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gauvreau</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ouellette</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Fortier</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Raelson</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sherbatich</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Riazanskaia</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rogaev</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Raeymaekers</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aerssens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Konings</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Luyten</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Macciardi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sham</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Straub</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D</given-names>
</name>
</person-group>. (<year>2002</year>). <article-title>Genetic and physiological data implicating the new human gene G72 and the gene for <sc>d</sc>-amino acid oxidase in schizophrenia</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>99</volume>, <fpage>13675</fpage>–<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr4-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Aniello</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>D'Onofrio</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pischetola</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>D'Aniello</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vetere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Petrucelli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>G. H.</given-names>
</name>
</person-group> (<year>1993</year>). <article-title>Biological role of <sc>d</sc>-amino acid oxidase and <sc>d</sc>-aspartate oxidase. Effects of <sc>d</sc>-amino acids</article-title>. <source>J Biol Chem</source> <volume>268</volume>, <fpage>26941</fpage>–<lpage>949</lpage>.</citation>
</ref>
<ref id="bibr5-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Day</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Heussner</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Propiverine-induced protein accumulation in F344 rats. Site specific excision and subsequent identity confirmation of accumulated DAAO in renal proximal tubules via MALDI-TOF/ TOF-MS</article-title>. <source>Toxicol Sci</source> <volume>90</volume>, <fpage>97</fpage>.</citation>
</ref>
<ref id="bibr6-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dietrich</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Heussner</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>O'Brien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gramatté</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Runkel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rumpf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>B. W</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Propiverine-induced accumulation of nuclear and cytosolic protein in F344 rat kidneys: Isolation and identification of the accumulating protein</article-title>. <source>Toxicol Appl Pharmacol</source> <volume>233</volume>, <fpage>411</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr7-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldenberg</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mayskiy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mossey</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ruthazer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia</article-title>. <source>Arthritis Rheum</source> <volume>39</volume>, <fpage>1852</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr8-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gracely</surname>
<given-names>R. H.</given-names>
</name>
<name>
<surname>Petzke</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Clauw</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia</article-title>. <source>Arthritis Rheum</source> <volume>46</volume>, <fpage>1333</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr9-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gramatte</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Runkel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Heussner</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kumpf</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>D.R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Propiverine-induced protein accumulation in F344 rats: Confirmation of identity and intra-renal localization of accumulated DAAO via Western-blot and immunohistochemistry</article-title>. <source>Toxicol Sci</source> <volume>90</volume>, <fpage>97</fpage>.</citation>
</ref>
<ref id="bibr10-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heussner</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Day</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Gramatte</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Runkel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rumpf</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>D. R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Propiverine-induced protein accumulation in F344 rats: Protein identification</article-title>. <source>Toxicol Sci</source> <volume>90</volume>, <fpage>97</fpage>.</citation>
</ref>
<ref id="bibr11-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koibuchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Matsuzaki</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ohtake</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yamaoka</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>1995</year>). <article-title>Localization of <sc>d</sc>-amino acid oxidase mRNA in the mouse kidney and the effect of testosterone treatment</article-title>. <source>Histochem Cell Biol</source> <volume>104</volume>, <fpage>349</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr12-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>R</given-names>
</name>
</person-group>. (<year>1998</year>). <article-title>Rat <sc>d</sc>-amino-acid oxidase cDNA. Rat <sc>d</sc>-amino-acid oxidase as  an intermediate form between mouse and other mammalian <sc>d</sc>-amino-acid oxidases</article-title>. <source>Biochim Biophys Acta</source> <volume>1395</volume>, <fpage>165</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr13-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Assignment of <sc>d</sc>-amino-acid oxidase gene to a human and a mouse chromosome</article-title>. <source>Amino Acids</source> <volume>20</volume>, <fpage>401</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr14-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hamase</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Zaitsu</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Mutant mice and rats lacking <sc>d</sc>-amino acid oxidase</article-title>. <source>Chem Biodivers</source> <volume>7</volume>, <fpage>1450</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr15-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konno</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Summer</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Niwa</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Mutant rat strain lacking <sc>d</sc>-amino-acid oxidase</article-title>. <source>Amino Acids</source> <volume>37</volume>, <fpage>367</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr16-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kyle</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Dugan</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Testerman</surname>
<given-names>K. K.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Milnacipran for treatment of fibromyalgia</article-title>. <source>Ann Pharmacother</source> <volume>44</volume>, <fpage>1422</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr17-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lawson</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>Tricyclic antidepressants and fibromyalgia: What is the mechanism of action?</article-title> <source>Expert Opin Investig Drugs</source> <volume>11</volume>, <fpage>1437</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr18-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maekawa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kasai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Summer</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>R</given-names>
</name>
</person-group>. (<year>2005</year>). <article-title>
<sc>d</sc>-amino-acid oxidase is involved in <sc>d</sc>-serine-induced nephrotoxicity</article-title>. <source>Chem Res Toxicol</source> <volume>18</volume>, <fpage>1678</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr19-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitchell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.-J.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Payling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Falchi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Habgood</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Panoutsou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Winkler</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tisato</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Hajitou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vance</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shaw</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mazarakis</surname>
<given-names>N. D.</given-names>
</name>
<name>
<surname>de Belleroche</surname>
<given-names>J</given-names>
</name>
</person-group>. (<year>2010</year>). <article-title>Familial amyotrophic lateral sclerosis is associated with a mutation in <sc>d</sc>-amino acid oxidase</article-title>. <source>Proc Natl Acad Sci USA</source> <volume>107</volume>, <fpage>7556</fpage>.</citation>
</ref>
<ref id="bibr20-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kuwata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hasegawa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Irimura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maruden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Irimura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Maruden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morita</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1989</year>). <article-title>Thirteen-week oral toxicity study of propiverine hydrochloride in rats</article-title>. <source>J Toxicol Sci</source> <volume>14</volume>, <fpage>13</fpage>–<lpage>59</lpage>.</citation>
</ref>
<ref id="bibr21-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nijs</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Houdenhove</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>From acute musculoskeletal pain to chronic widespread pain and fibromyalgia: Application of pain neurophysiology in manual therapy practice</article-title>. <source>Man Ther</source> <volume>14</volume>, <fpage>3</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr22-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohide</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Miyoshi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hamase</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Konno</surname>
<given-names>R</given-names>
</name>
</person-group>. (<year>2011</year>). <article-title>
<sc>d</sc>-Amino acid metabolism in mammals: Biosynthesis, degradation and analytical aspects of the metabolic study</article-title>. <source>J Chromatogr B Analyt Technol Biomed Life Sci</source> <volume>879</volume>, <fpage>3162</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr23-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Ram</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>F. J.</given-names>
</name>
<name>
<surname>Waxman</surname>
<given-names>D. J.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate</article-title>. <source>Mol Pharmacol</source> <volume>50</volume>, <fpage>67</fpage>–<lpage>74</lpage>.</citation>
</ref>
<ref id="bibr24-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Runkel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rumpf</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heussner</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gramatte</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dietrich</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Propiverine-induced protein accumulation in F344 rats: Reversibility of pathological changes and protein accumulation</article-title>. <source>Toxicol Sci</source> <volume>90</volume>, <fpage>97</fpage>.</citation>
</ref>
<ref id="bibr25-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staud</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vierck</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mauderli</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>D. D.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome</article-title>. <source>Pain</source> <volume>91</volume>, <fpage>165</fpage>–<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr26-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stefanini</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nardacci</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Farioli-Vecchioli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pajalunga</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sartori</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Liver and kidney peroxisomes in lactating rats and their pups after treatment with ciprofibrate. Biochemical and morphometric analysis</article-title>. <source>Cell Mol Biol (Noisy-le-grand)</source> <volume>45</volume>, <fpage>815</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr27-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamashita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kuwata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Irimura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Morinaga</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ashizawa</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Fifty-two-week oral chronic toxicity study of propiverine hydrochloride in rats</article-title>. <source>J Toxicol Sci</source> <volume>15</volume>, <fpage>107</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr28-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Michele</surname>
<given-names>D. E.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Brosius</surname>
<given-names>III, F. C</given-names>
</name>
<name>
<surname>Schnermann</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Briggs</surname>
<given-names>J. P</given-names>
</name>
</person-group>. (<year>1999</year>). <article-title>Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney</article-title>. <source>Am J Physiol</source> <volume>277</volume>, <fpage>966</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr29-0192623312450629">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Angermüller</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Völkl</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fahimi</surname>
<given-names>H. D.</given-names>
</name>
</person-group> (<year>1986</year>). <article-title>Pipecolic acid is oxidized by renal and hepatic peroxisomes. Implications for Zellweger's cerebro-hepato-renal syndrome (CHRS)</article-title>. <source>Exp Cell Res</source> <volume>164</volume>, <fpage>267</fpage>–<lpage>71</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>